Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ORTX

Orchard Therapeutics (ORTX) Stock Price, News & Analysis

Orchard Therapeutics logo

About Orchard Therapeutics Stock (NASDAQ:ORTX)

Advanced Chart

Key Stats

Today's Range
$16.70
$16.70
50-Day Range
$16.40
$16.70
52-Week Range
$4.24
$16.72
Volume
N/A
Average Volume
157,287 shs
Market Capitalization
$380.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd..

Receive ORTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ORTX Stock News Headlines

DOGE To DO List
Elon's found so much waste he's now claiming "the magnitude of the fraud in federal entitlements" is greater than "the combined sum of every private scam you've ever heard by FAR"... And while this is disturbing and even infuriating to see our tax money literally wasted... there IS a solution. I believe it's Elon's ultimate end game.
See More Headlines

ORTX Stock Analysis - Frequently Asked Questions

Orchard Therapeutics plc (NASDAQ:ORTX) issued its quarterly earnings results on Monday, May, 15th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($1.61) by $1.49. The company earned $1.24 million during the quarter, compared to analyst estimates of $6.48 million. Orchard Therapeutics had a negative net margin of 333.90% and a negative trailing twelve-month return on equity of 74.94%.

Orchard Therapeutics shares reverse split on the morning of Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Orchard Therapeutics (ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Orchard Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
5/15/2023
Today
2/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ORTX
Fax
N/A
Employees
166
Year Founded
N/A

Profitability

Net Income
$-150,660,000.00
Net Margins
-333.90%
Pretax Margin
-334.54%

Debt

Sales & Book Value

Annual Sales
$22.66 million
Book Value
$7.74 per share

Miscellaneous

Free Float
22,099,000
Market Cap
$380.09 million
Optionable
Optionable
Beta
0.55
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:ORTX) was last updated on 2/24/2025 by MarketBeat.com Staff
From Our Partners